Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
MUCINEX D is an oral extended-release tablet combining guaifenesin (expectorant) and pseudoephedrine HCl (decongestant) approved in 2004 for over-the-counter use. It is indicated for temporary relief of chest congestion and nasal congestion due to colds, bronchitis, or flu. The drug works by thinning mucus secretions and reducing nasal swelling to improve airway clearance.
Approaching loss of exclusivity signals potential brand team downsizing and shift toward cost-containment and generic transition strategies.
Expectorant
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg Under Fasting Conditions
Working on MUCINEX D in a LOE-approaching environment offers exposure to brand defense, generic transition, and cost-containment strategies rather than growth. Limited linked job postings reflect the mature, stable nature of the asset and declining headcount as the product enters generics phase.
Worked on MUCINEX D at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.